Xiao Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiao Liang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ravil N. Khaybullin
Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
2 shared publications - Xin Qi
Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
2 shared publications Alan R. Katritzky
Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA
1 shared publication- Junjie Fu
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Lihu Avenue 1800, Wuxi, Jiangsu 214122, China
1 shared publication - Mei Zhang
Department of Radiation Oncology, College of Medicine, University of Florida Health Cancer Center, Gainesville, FL 32610, USA
1 shared publication - Paul Okunieff
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville and Jacksonville, FL, USA
1 shared publication
Latest Publications
- Open Access
(S)-N-(N-(((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfamoyl)-5-oxopyrrolidine-2-carboxamide
Aminoacyl sulfamides represent a family of high-affinity inhibitors of the specific aminoacyl tRNA synthetase activity. In this paper we describe the synthesis of a novel sulfamide adenosine derivative 4 bearing pyroglutamyl fragment (pGlu-SA).
Open Access(S)-N-(N-(((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfamoyl)-5-oxopyrrolidine-2-carboxamide
Aminoacyl sulfamides represent a family of high-affinity inhibitors of the specific aminoacyl tRNA synthetase activity. In this paper we describe the synthesis of a novel sulfamide adenosine derivative 4 bearing pyroglutamyl fragment (pGlu-SA).
- Open Access
Design and Synthesis of Isosteviol Triazole Conjugates for Cancer Therapy
One of the keys for successfully developing drugs against the broad spectrum of cancer cell types is structural diversity. In the current study, we focused on a family of isosteviol derivatives as potential novel antitumor agents. Isosteviol is a tetracyclic diterpenoid obtained by acid hydrolysis of steviol glycoside extracts isolated from abundant Stevia rebaudiana plants. In this work, we have designed and synthesized a panel of isosteviol triazole conjugates using “click” chemistry methodology. Evaluation of these compounds against a series of cancer cell lines derived from primary and metastatic tumors demonstrated that these conjugates exhibit cytotoxic activities with IC50 in the low μM range. In addition, their anti-proliferative activities are cancer cell type specific. Taken together, our studies underscore the importance of structural diversity in achieving cancer cell type specific drug development.
Open AccessDesign and Synthesis of Isosteviol Triazole Conjugates for Cancer Therapy
One of the keys for successfully developing drugs against the broad spectrum of cancer cell types is structural diversity. In the current study, we focused on a family of isosteviol derivatives as potential novel antitumor agents. Isosteviol is a tetracyclic diterpenoid obtained by acid hydrolysis of steviol glycoside extracts isolated from abundant Stevia rebaudiana plants. In this work, we have designed and synthesized a panel of isosteviol triazole conjugates using “click” chemistry methodology. Evaluation of these compounds against a series of cancer cell lines derived from primary and metastatic tumors demonstrated that these conjugates exhibit cytotoxic activities with IC50 in the low μM range. In addition, their anti-proliferative activities are cancer cell type specific. Taken together, our studies underscore the importance of structural diversity in achieving cancer cell type specific drug development.